Patent US4985437A successfully refreshed from Google Patents.
US4985437A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medicaments
Assignee: Glaxo Group Ltd
•
Filing: 1987-12-16
•
Granted: 1991-01-15
•
Expires: 2007-12-16
Abstract
Abstract The invention relates to the use of certain compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT 3 receptors for the treatment of cognitive disorders such as attentional and memory deficits and dementia states.
Inventors
- 👤 Michael B. Tyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:23
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61K31/41; A61K31/415; A61K31/435; A61K31/44; A61K31/445; A61K31/46; A61K31/495; A61K31/50; A61P; A61P25/00; A61P25/28; A61P43/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
197 words
A method for the treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or another cognitive disorder an effective amount for the treatment of said dementia or other cognitive disorder of a compound of formula I TABLE I
______________________________________
Design Parameters for a Narrow-Band Optical Interference Filter
of the 1.0 HL HH LHLHL HH L'H 1.0 Type
Optical Thin Film Filter
(Pass Wavelength = 1.00 um)
Refractive
Thickness
Index (A)
______________________________________
Input Region 1.00 . . .
Region 1 (H) 4.00 625.000
Region 2 (L) 1.35 1851.852
Region 3 (L') 1.83 1366.120
Output Region 1.00 . . .
______________________________________ wherein R 1 and R 2 independently represent hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 )alkylamino, mercapto or C 1-4 alkylthio; R 3 represents hydrogen, C 1-4 alkyl, C 3-5 alkenyl, aryl or aralkyl; R 4 represents hydrogen, C 1-7 alkyl, C 3-5 alkenyl or aralkyl; n is 2 or 3; the free valence is attached to either fused ring, and the azabicyclic ring is in either the exo or endo configuration; or a physiologically acceptable salt or solvate thereof.
Claim 2
Independent Claim
197 words
A method for the treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or another cognitive disorder an effective amount for the treatment of said dementia or other cognitive disorder of a compound of formula I TABLE I
______________________________________
Design Parameters for a Narrow-Band Optical Interference Filter
of the 1.0 HL HH LHLHL HH L'H 1.0 Type
Optical Thin Film Filter
(Pass Wavelength = 1.00 um)
Refractive
Thickness
Index (A)
______________________________________
Input Region 1.00 . . .
Region 1 (H) 4.00 625.000
Region 2 (L) 1.35 1851.852
Region 3 (L') 1.83 1366.120
Output Region 1.00 . . .
______________________________________ wherein R 1 and R 2 independently represent hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 )alkylamino, mercapto or C 1-4 alkylthio; R 3 represents hydrogen, C 1-4 alkyl, C 3-5 alkenyl, aryl or aralkyl; R 4 represents hydrogen, C 1-7 alkyl, C 3-5 alkenyl or aralkyl; n is 2 or 3; the free valence is attached to either fused ring, and the azabicyclic ring is in either the exo or endo configuration; or a physiologically acceptable salt or solvate thereof.
Claim 3
Dependent Claim
58 words
A method according to claim 1 wherein R 1 and R 2 independently represent hydrogen, halogen or C 1-4 alkyl; R 3 represents hydrogen or C 1-4 alkyl; R 4 represents hydrogen, C 1-7 alkyl or aralkyl; the carbonyl group is attached to the 3-position of the indole ring, and the azabicyclic ring is in the endo configuration.
Claim 4
Dependent Claim
33 words
A method according to claim 1 wherein said compound selected from compounds of formula (I) is administered in a dose of 0.5 μg to 20 mg from 1 to 4 times per day.
Claim 5
Dependent Claim
33 words
A method according to claim 1 wherein said compound selected from compounds of formula (I) is administered in a dose of 0.05 mg to 10 mg from 1 to 4 times per day.
Claim 6
Independent Claim
52 words
A method for the treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or another cognitive disorder an effective amount for the treatment of said dementia or other cognitive disorder of -(3α-tropanyl)-1H-indole-3-carboxylic acid ester or a physiologically acceptable salt or solvate thereof.
Claim 7
Independent Claim
52 words
A method for the treatment of dementia and other cognitive disorders which comprises administering to a human or animal subject suffering from dementia or another cognitive disorder an effective amount for the treatment of said dementia or other cognitive disorder of -(3α-tropanyl)-1H-indole-3-carboxylic acid ester or a physiologically acceptable salt or solvate thereof.
References Cited (Backward Citations)
GB2125398A
Cited
US4803199A
Cited
US4789673A
Cited
EP0189002A2
Cited
US4826838A
Cited
EP0190920A2
Cited
US4721720A
Cited
US4851407A
Cited
US4721720B1
Cited
US4624961A
Cited
GB2193633A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-01-14 | 1994-07-16 | 1995-01-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-01-14 | 1998-07-16 | 1999-01-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-01-14 | 2002-07-16 | 2003-01-15 | $7700.00 | Window Closed / Lapsed |